Home > Boards > Free Zone > Health and Sciences > Biotech Values

AGN, EDIT announce mutual opt-ins on EDIT-101:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 728
Posts 109,914
Boards Moderated 15
Alias Born 09/05/02
160x600 placeholder
DewDiligence Member Level  Monday, 08/06/18 04:17:39 PM
Re: DewDiligence post# 209848
Post # of 227510 
AGN, EDIT announce mutual opt-ins on EDIT-101:

https://www.prnewswire.com/news-releases/allergan-and-editas-medicine-announce-exercise-of-options-to-jointly-develop-crispr-genome-editing-experimental-medicine-edit-101-300692493.html
Quote:
…[Allergan] has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.

Under the terms of the option agreement signed in March 2017 [#msg-129491806], Allergan has paid Editas Medicine a fee of $15 million in conjunction with the exercise of its option. Editas Medicine is eligible to receive an additional $25 million from Allergan upon acceptance of an investigational new drug (IND) application for EDIT-101 by the Food & Drug Administration (FDA).



“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist